



WHAT IS CLAIMED IS:

1. A compound of Formula (I), or salt thereof:



(I)

or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:



ring A is-

~~W is N, or CR¹⁶;~~

~~W', at each occurrence, is independently selected from N, O, S and CR¹⁶, wherein at least one W' is not CR¹⁶, and at most only one W' is selected as O or S;~~

~~R¹ and R² are independently selected from H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ alkoxyalkyl, and C₃-C₆ cycloalkyl;~~

~~alternatively, R¹ and R², together with the atom to which they are attached, join together to form a C₃-C₆ cycloalkyl, or a 4 to 6 membered heterocycle having 1-2 heteroatoms, the cycloalkyl or heterocycle is substituted with 0-4 F and 0-1 OH;~~

~~R¹⁶, at each occurrence, is independently selected from H, F, Cl, Br, I, CN, OH, N(R^a)₂, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, C₁-C₄ hydroxyalkyl, C₁-C₃ haloalkoxy, C₃-C₆ cycloalkyl, and C₃-C₆ halocycloalkyl~~

~~R^a is, at each occurrence, independently selected from H, F, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-hydroxyalkyl, and C₃-C₆-cycloalkyl;~~

~~or two R^a, along with the nitrogen atom to which they are attached, join to form a 5 to 6 membered heterocycle containing 0-2 additional heteroatoms selected from N, O and S;~~


~~Y is 5-tetrazolyl, SO₃H, PO₂H, PO₃H₂, COOR,~~

R^Z is at each occurrence independently selected from H, C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl, C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl or, alternatively, two R^Z groups either on the same atom or on adjacent atoms can join to form a C₃-C₆-cycloalkyl or a 4 to 7 membered heterocycle containing 1-2 heteroatoms selected from N, O and S;


G is selected from a 4 to 11 membered heterocycle having 1-4 atoms selected from N, O, and S, a C₃-C₆-cycloalkyl, C₆-C₁₀-aryl or a 5 to 10 membered heteroaryl having 1-4 atoms selected from N, O, and S; wherein the heterocycle, cycloalkyl, aryl and heteroaryl a phenyl, thiophenyl, quinolinyl, isoquinolinyl, indolyl, pyrazolyl, pyrrolyl, pyridinyl, isoindolinyl, pyrrolidinyl; any of which are substituted with 0-3 substituents independently selected from the group consisting of =O, F, Cl, Br, I, $\underline{F}$, C₁-C₆-alkyl, ~~C₁-C₆-alkoxy~~, C₁-C₆-haloalkyl, C₁-C₆-hydroxyalkyl, OH, OR^x, ~~SR^x~~, N(R^x)₂, CO(R^x), CON(R^x)₂, CO₂R^x, N(R^x)CO₂(R^x), N(R^x)CO(R^x), N(R^x)CON(R^x)₂, S(O)₂(R^x), S(O)₂R^x, S(O)₂N(R^x)₂, ~~or~~ N(R^x)S(O)₂(R^x) or N(R^x)S(O)₂R^x;


R^x is H, C₁₋₆ alkyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, phenyl, CH₂-phenyl;

ring B is




Group C is





R^3 is C_{1-4} hydroxyalkyl, C_{1-4} haloalkyl, C_{1-6} -hydroxycycloalkyl, C_{1-6} -halocycloalkyl,



R^4 is H, F, Cl, Br, CF₃, CN, N(R^Z)₂, CON(R^Z)₂, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxyalkyl, C_{1-4} hydroxyalkyl, C_{1-6} -cycloalkyl, C_{1-6} -halocycloalkyl, C_{1-6} -alkoxycycloalkyl, or C_{1-6} -hydroxycycloalkyl;


R^5 is C_{1-6} alkyl, C_{1-6} haloalkyl; C_{1-6} alkoxyalkyl, C_{1-6} -cycloalkyl- C_{0-4} -alkyl which may be substituted with 1-3 halogens or a C_{1-3} -alkoxy group;

~~R^6 is H, F, Cl, Br, CF₃, CN, N(R^Z)₂, CON(R^Z)₂, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxyalkyl, C_{1-4} hydroxyalkyl, C_{1-6} -cycloalkyl, C_{1-6} -halocycloalkyl, C_{1-6} -alkoxycycloalkyl, or C_{1-6} -hydroxycycloalkyl; and~~

R^Z is at each occurrence independently selected from H, C_{1-4} -alkyl, C_{1-4} -hydroxyalkyl, C_{1-4} -haloalkyl, and C_{3-6} -cycloalkyl or, alternatively, two R^Z groups on the same atom can join to form a 4 to 7 membered heterocycle containing 1-2 heteroatoms selected from N, O and S; and


R^7 and R^8 , are independently selected from H, C_{1-4} -alkyl, C_{1-4} -hydroxyalkyl, C_{1-4} -haloalkyl, C_{3-6} -cycloalkyl or, alternatively, R^7 and R^8 , along with the atom to which they are attached, can join to form a C_{3-6} -cycloalkyl, a C_{3-6} -halocycloalkyl, a C_{3-6} -hydroxycycloalkyl or a 4 to 7 membered heterocycle having 1-2 heteroatoms selected from N, O, or S and optionally substituted ~~the potential for further substitution~~ with 1-4 F, OH, C_{1-4} -alkyl, C_{1-4} -haloalkyl, C_{1-4} -alkoxyalkyl, C_{1-4} -hydroxyalkyl;

provided the compounds of Formula (I) are not



~~2. A compound of claim 1, or salt thereof, wherein~~


~~Group C is~~



~~23. A compound of claim 1, or salt thereof, wherein~~

~~R¹ and R² are H;~~

~~R³ is H, C₁₋₂ hydroxyalkyl, CO₂H, CO₂-C₁₋₆-alkyl, CONH₂, CONH(C₁₋₆-alkyl),~~



~~CON(C₁₋₆-alkyl)₂, or~~

~~R⁴ is H, F, Cl, Br, CF₃, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, or C₁₋₂ hydroxyalkyl;-~~


~~R⁵ is C₁₋₆ alkyl, or C₃₋₆ cycloalkyl or O(C₁₋₆-alkyl);~~

~~R⁶ is hydrogen, or C₁₋₄ alkyl;~~

~~R⁷ and R⁸ are H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, or C₁₋₃ hydroxyalkyl~~

~~alternatively, R⁷ and R⁸, along with the atom to which they are attached, join to form a~~



~~C₃-C₆-cycloalkyl or a C₄-C₇-heterocycle; and~~



~~R is H, C₁₋₆ alkyl, or C₁₋₆ hydroxyalkyl;- or~~

~~34. A compound of claims 1-3, or salt thereof, wherein;~~

~~Group C is~~



R^3 is C_{1-4} hydroxyalkyl, CO_2H , or

R^4 is C_{1-3} alkyl, C_{1-3} haloalkyl, or C_{1-3} hydroxyalkyl; and

R^5 is ethyl, n-propyl, or n-butyl.


45. A compound of claims 1-4, or salt thereof, wherein:

G is selected from a 5 to 10 membered heterocycle having 1-3 atoms selected from N, O, and S, phenyl or a C_6 - C_{10} heteroaryl having 1-3 atoms selected from N, O, and S; wherein the heterocycle, phenyl and heteroaryl are substituted with 0-3 substituents independently selected from the group consisting of $-O$, Cl, Br, I, F, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkyl, C_1 - C_6 alkylthio, C_1 - C_6 hydroxyalkyl, OH, OR^x , $N(R^x)_2$, $CO(R^x)$, $CON(R^x)_2$, CO_2R^x , $N(R^x)CO_2(R^x)$, $N(R^x)CO(R^x)$, $N(R^x)CON(R^x)_2$, $S(O)_2(R^x)$, $S(O)_2R^x$, $S(O)_2N(R^x)_2$, $N(R^x)S(O)_2(R^x)$, or $N(R^x)S(O)_2R^x$;


$-R^x$ is H, C_{1-6} alkyl, CF_3 , phenyl, or CH_2 -phenyl.

56. A compound of claims 1-5, or salt thereof, wherein:

Ring B is




any of which are optionally substituted with 0-2 F,



67. A compound of claims 1-4, or salt thereof, wherein:

Y is COOH, 5-tetrazolyl, SO₃H,




and

R^s is is-C₁₋₆ alkyl, C₆₋₁₀-aryl-C₁-C₆-alkyl or (CH₂-phenyl)Ph).

78. A compound of claims 1-7, or salt thereof, wherein:

Ring A is



R^a is H or F.

89. A compound of claims 1-8, or salt thereof, wherein:


G is selected from a phenyl, thiophenyl, quinolinyl, isoquinolinyl, indolyl, pyrazolyl, pyrrolyl, pyridinyl, isoindolinyl, pyrrolidinyl; any of which are substituted with 0-3 substituents independently selected from the group consisting of -O, Cl, Br, I, F, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-hydroxyalkyl, OH, OR^{*}, N(R^{*})₂, CO(R^{*}),

~~CON(R^{*})₂, CO₂R^{*}, N(R^{*})CO₂(R^{*}), N(R^{*})CO(R^{*}), N(R^{*})CON(R^{*})₂, S(O)₂(R^{*}),
S(O)₂R^{*}, S(O)₂N(R^{*})₂, N(R^{*})S(O)₂(R^{*}), or N(R^{*})S(O)₂R^{*};~~

R^x is H, C₁₋₃ alkyl, CF₃, phenyl, or CH₂-phenyl.

~~910. A compound of claims 1-9, or salt thereof, wherein:~~


Y is COOH, 5-tetrazolyl,



R^s is C₁₋₆ alkyl.

~~11. A compound of claims 1-10, or salt thereof, wherein~~


Ring B is




~~any of which are substituted with 0-2 F.~~

~~12. A compound of claims 1-11, or salt thereof, wherein~~

Ring B is



Ring A is



Z is a bond or NR⁵;

G is isoindoliny-1,3-dione, pyrrolidine-2,5-dione, phenyl, thiazolyl, pyridinyl, pyrrolyl, pyrazolyl, quinoliny-1, isoquinoliny-1, any of which may be substituted with 0-3 substituents selected from -O-, C₁₋₄ alkyl, -O-R^{*}, C₁₋₄ haloalkyl, -C(O)NR^{*}, -N(R^{*})₂, and F;


R⁵ is C₃₋₄ alkyl;

~~R⁶ is C₃₋₄ alkyl;~~


~~R^a is hydrogen, C₁₋₄ alkyl, and C₁₋₂ haloalkyl; and~~

~~Y is tetrazolyl, COOH, 1,2,4-oxadiazol-5(4H)-one, or SO₂NHCOO-nbutyl.~~

1013. A compound of Fformula (I), or salt thereof:



or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:



~~W is N, or CR¹⁶;~~

~~W', at each occurrence, is independently selected from N, O, S and CR¹⁶ where at least one W is not CR¹⁶, and at most only one W is selected as O or S;~~


~~R¹ and R² are independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ alkoxyalkyl, and C₃₋₆ cycloalkyl;~~

~~alternatively, R¹ and R², together with the atom to which they are attached, join together to form a C₃₋₆ cycloalkyl, or a 4 to 6 membered heterocycle having 1-2 heteroatoms, the cycloalkyl or heterocycle is substituted with 0-4 F and 0-1 OH;~~
~~R¹⁶, at each occurrence, is independently selected from H, F, Cl, Br, I, CN, OH, N(R^a)₂, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₃ haloalkoxy, C₃₋₆ cycloalkyl, and C₃₋₆ halocycloalkyl~~

R^a is, at each occurrence, independently selected from H, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-hydroxyalkyl, and C₃-C₆-cycloalkyl;

or two R^a , along with the nitrogen atom to which they are attached, join to form a 5 to 6 membered heterocycle containing 0-2 additional heteroatoms selected from N, O and S;

Y is 5-tetrazolyl, SO₃H, PO₂H₂, PO₃H₂, COOR,



R , at each occurrence, is independently selected from H, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-hydroxyalkyl, C₃-C₇-cycloalkyl, C₆₋₁₀-aryl-C₁-C₆-alkyl, heterocycle-C₁-C₆-alkyl, wherein said heterocycle is a 4-10 membered group having 1-3 heteroatoms selected from N, O, or S, said aryl and heterocycle are each substituted with 0-3 groups chosen from C₁-C₃-alkyl, halo, OH, or C₁-C₃-fluoroalkyl;

R^s at each occurrence, is independently selected from H, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-hydroxyalkyl, C₃-C₇-cycloalkyl, C₃-C₇-cycloalkyl-C₁-C₃-alkyl, C₆₋₁₀-aryl, C₆₋₁₀-aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heterocyclyl, heterocycle-C₁-C₆-alkyl, wherein the heteroaryl and heterocycle are each a 4-10 membered group having 1-3 heteroatoms selected from N, O, or S;


Z, at each occurrence, is independently selected from a bond, O, S, $N(R^z)$, $C(R^z)_2$, $C=O$, $C(=O)N(R^z)$, $N(R^z)C(=O)$, $C(R^z)_2C(R^z)_2$, $OC(R^z)_2$, $SC(R^z)_2$, $N(R^z)C(R^z)_2$, $C(R^z)_2O$, $C(R^z)_2S$, $C(R^z)_2N(R^z)$ is a bond;

R^z is at each occurrence independently selected from H, C_1 - C_4 -alkyl, C_1 - C_4 -hydroxyalkyl, C_1 - C_4 -haloalkyl, C_3 - C_6 -cycloalkyl or, alternatively, two R^z -groups either on the same atom or on adjacent atoms can join to form a C_3 - C_6 -cycloalkyl or a 4 to 7 membered heterocycle containing 1-2 heteroatoms selected from N, O and S;


G is selected from a 4 to 11 membered heterocycle having 1-4 atoms selected from N, O, and S, a C_3 - C_8 -cycloalkyl, C_6 - C_{10} -aryl or a 5 to 10 membered heteroaryl having 1-4 atoms selected from N, O, and S; wherein the heterocycle, cycloalkyl, aryl and heteroaryl are substituted with 0-3 substituents independently selected from the group consisting of $-O$, F, Cl, Br, I, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -haloalkyl, C_1 - C_6 -hydroxyalkyl, OH, OR^x , SR^x , $N(R^x)_2$, $CO(R^x)$, $CON(R^x)_2$, CO_2R^x , $N(R^x)CO_2(R^x)$, $N(R^x)CO(R^x)$, $N(R^x)CON(R^x)_2$, $S(O)_2(R^x)$, $S(O)_2N(R^x)_2$, or $N(R^x)S(O)_2(R^x)$ isoindolinyl-1,3-dione, pyrrolidine-2,5-dione, phenyl, thiazolyl, pyridinyl, pyrrolyl, pyrazolyl, quinolinyl, isoquinolinyl, any of which may be substituted with 0-3 substituents selected from $=O$, C_{1-4} alkyl, $-OR^x$, C_{1-4} haloalkyl, $-C(O)NR^x$, $-N(R^x)_2$, and F;

R^x is H, C_{1-6} alkyl, C_{1-4} -haloalkyl, C_{1-4} -hydroxyalkyl, phenyl, CH_2 -phenyl;

ring B is




Group C



IC

R³ is C₁₋₄ hydroxyalkyl, C₁₋₄ haloalkyl, C₁₋₆-hydroxycycloalkyl, C₁₋₆-halocycloalkyl,



COOR, CON(R^z)₂, or

R, at each occurrence, is independently selected from H, C₁₋₆ alkyl, C₁₋₆-haloalkyl, C₁₋₆-hydroxyalkyl, C₃₋₇ cycloalkyl, C₆₋₁₀-aryl-C₁₋₆ alkyl, heterocycle-C₁₋₆ alkyl, wherein said heterocycle is a 4-10 membered group having 1-3 heteroatoms selected from N, O, or S, said aryl and heterocycle are each substituted with 0-3 groups chosen from C₁₋₃ alkyl, halo, OH, or C₁₋₃ fluoroalkyl;

R⁴ is H, F, Cl, Br, CF₃, CN, N(R^z)₂, CON(R^z)₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl C₁₋₄ alkoxyalkyl, C₁₋₄ hydroxyalkyl, C₁₋₆-cycloalkyl, C₁₋₆-halocycloalkyl, C₁₋₆-alkoxycycloalkyl, or C₁₋₆-hydroxycycloalkyl;

R⁵ is C₁₋₆ alkyl, C₁₋₆ haloalkyl C₁₋₆ alkoxyalkyl, C₁₋₃ cycloalkyl C₀₋₄ alkyl which may be substituted with 1-3 halogens or a C₁₋₃ alkoxy group C₃₋₄ alkyl;

R^z is at each occurrence independently selected from H, C₁₋₄-alkyl, C₁₋₄-hydroxyalkyl, C₁₋₄-haloalkyl, and C₃₋₆-cycloalkyl or, alternatively, two R^z groups on the same atom can join to form a 4 to 7 membered heterocycle containing 1-2 heteroatoms selected from N, O and S;


R⁷ and R⁸, are independently selected from H, C₁₋₄-alkyl, C₁₋₄-hydroxyalkyl, C₁₋₄-haloalkyl, C₃₋₆-cycloalkyl or, alternatively, R⁷ and R⁸, along with the atom to which they are attached, can join to form a C₃₋₆-cycloalkyl, a C₃₋₆-halocycloalkyl, a C₃₋₆-hydroxycycloalkyl or a 4 to 7 membered heterocycle having 1-2 heteroatoms selected from N, O, or S and optionally substituted with 1-4 F, OH, C₁₋₄-alkyl, C₁₋₄-haloalkyl, C₁₋₄-alkoxyalkyl, C₁₋₄-hydroxyalkyl; and








Y is tetrazolyl, COOH, 1,2,4-oxadiazol-5(4H)-one, or -SO₂NHCOO-nbutyl; R⁶ is H, F, Cl, Br, CF₃, CN, N(R^z)₂, CON(R^z)₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl C₁₋₄ alkoxyalkyl, C₁₋₄ hydroxyalkyl, C₃₋₆-cycloalkyl, C₃₋₆-halocycloalkyl, C₃₋₆-alkoxycycloalkyl, or C₃₋₆-hydroxycycloalkyl;







R⁹ is COOR, CON(R^z)₂; and


r is 0 to 3;





provided that the compounds of Formula (I) are not































~~14. A compound of claim 13, or salt thereof, wherein~~

~~R^5 is C_{1-6} -alkyl, C_{3-6} -cycloalkyl or $O(C_{1-6}$ -alkyl);~~

~~R^9 is CO_2H , CO_2-C_{1-6} -alkyl, CO_2NH_2 , $CO_2NH(C_{1-6}$ -alkyl), $CO_2N(C_{1-6}$ -alkyl)₂, and~~

~~R^6 is hydrogen, or C_{1-4} -alkyl.~~

~~15. A compound of claims 13-14, or salt thereof, wherein~~

~~G is selected from a 5 to 10 membered heterocycle having 1-3 atoms selected from N, O, and S, phenyl or a C_6-C_{10} -heteroaryl having 1-3 atoms selected from N, O, and S;~~

~~wherein the heterocycle, phenyl and heteroaryl are substituted with 0-3~~

~~substituents independently selected from the group consisting of =O, Cl, Br, I, F,~~

~~C_1-C_6 -alkyl, C_1-C_6 -alkoxy, C_1-C_6 -haloalkyl, C_1-C_6 -alkylthio, C_1-C_6 -hydroxyalkyl,~~


~~OH , OR^* , $N(R^*)_2$, $CO(R^*)$, $CON(R^*)_2$, CO_2R^* , $N(R^*)CO_2(R^*)$, $N(R^*)CO(R^*)$,~~

~~$N(R^*)CON(R^*)_2$, $S(O)_2(R^*)$, $S(O)_2N(R^*)_2$, or $N(R^*)S(O)_2R^*$;~~

~~R^* is H, C_{1-6} -alkyl, CF_3 , phenyl, CH_2 phenyl.~~

~~16. A compound of claims 13-15, or salt thereof, wherein~~


~~Ring B is~~



~~any of which are optionally substituted with 0-2 F,~~

~~17. A compound of claims 13-15, or salt thereof, wherein~~


Ring B is



any of which are optionally substituted with 0-2 F,




Y is ~~COOH, COOMe, COOEt, 5-tetrazolyl, SO₃H,~~



18. A compound of claims 13-15, or salt thereof, wherein


wherein Y is ~~COOH, 5-tetrazolyl, SO₃H,~~



R = ~~C₁₋₆-alkyl, C₆₋₁₀-aryl-C₁₋₆-alkyl, or (CH₂)₂Ph.~~

19. A compound of claims 13-18, or salt thereof, wherein

Ring A is




R^a is H or F.

20. A compound of claims 13-19, or salt thereof, wherein

G is selected from a phenyl, thiophenyl, quinolinyl, isoquinolinyl, indolyl, pyrazolyl, pyrrolyl, pyridinyl, isoindolinyl, pyrrolidinyl; ; any of which are substituted with 0-3 substituents independently selected from the group consisting of =O, Cl, Br, I, F, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₁₋₆-hydroxyalkyl, OH, OR^{*}, N(R^{*})₂, CO(R^{*}),


~~CON(R^{*})₂, CO₂R^{*}, N(R^{*})CO₂(R^{*}), N(R^{*})CO(R^{*}), N(R^{*})CON(R^{*})₂, S(O)₂(R^{*}),
S(O)₂N(R^{*})₂, or N(R^{*})S(O)₂R^{*};
R^{*} is H, C₁₋₃-alkyl, CF₃, phenyl, CH₂phenyl.~~

~~21. A compound of claims 13-19, or salt thereof, wherein
Y is carboxyl, 5-tetrazolyl,~~




~~R is C₁₋₆-alkyl.~~


~~22. A compound of claims 13-20, or salt thereof, wherein
Ring B is~~



~~23. A compound of claim 13, or salt thereof wherein
Ring B is~~



~~Ring A is~~



~~Z is a bond or NR^a;~~

~~G is isoindolinyl-1,3-dione, pyrrolidine-2,5-dione, phenyl, thiazolyl, pyridinyl, pyrrolyl,
pyrazolyl, quinolinyl, isoquinolinyl, any of which may be substituted with 0-3
substituents selected from -O, C₁₋₄-alkyl, -OR^{*}, C₁₋₄-haloalkyl, -C(O)NR^{*}, -
N(R^{*})₂, and F;~~

~~R⁵ is C₃₋₄-alkyl;~~

~~R⁶ is C₃₋₄alkyl;~~

~~R^a is hydrogen, C₁₋₄alkyl, and C₁₋₂haloalkyl; and~~

~~Y is tetrazolyl, COOH, 1,2,4-oxadiazol-5(4H)-one, or SO₂NHCOO-nbutyl.~~

~~24. A compound according to claim 1, or salt thereof, where the compound is selected from Examples 1-462.~~

~~25. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof.~~


~~26. A method for the treatment or prophylaxis of diseases or disorders which can be modulated by biased agonism or β -Arrestin agonism of the angiotensin II receptor, comprising administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of at least one of the compounds of claims 1-23, wherein the disease or disorder is preserved injection fraction heart failure, reduced injection heart failure, and/or renal disease.~~

~~27. A method for the treatment or prophylaxis of diseases or disorders which can be modulated by biased agonism or β -Arrestin agonism of the angiotensin II receptor of claim 23, wherein the compound is administered in combination with at least one other type of therapeutic agent.~~


~~28. A method for the treatment or prophylaxis of diseases or disorders, comprising administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of at least one of the compounds of claims 1-23, wherein the disease or disorder is preserved injection fraction heart failure, reduced injection heart failure, and/or renal disease.~~

~~29. A method for the treatment or prophylaxis of diseases or of claim 27, wherein the compound is administered in combination with at least one other type of therapeutic agent.~~

30. A compound of formula (X), or salt thereof:



or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:



ring A is

or

W is N, or CR¹⁶;

W', at each occurrence, is independently selected from N, O, S and CR¹⁶, wherein at least one W is not CR¹⁶, and at most only one W is selected as O or S;

R¹ and R² are independently selected from H, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, and C₃-C₆-cycloalkyl;

alternatively, R¹ and R², together with the atom to which they are attached, join together to form a C₃-C₆-cycloalkyl, or a 4 to 6 membered heterocycle having 1-2 heteroatoms, the cycloalkyl or heterocycle is substituted with 0-4 F and 0-1 OH;


R¹⁶, at each occurrence, is independently selected from H, F, Cl, Br, I, CN, OH, N(R^a)₂,

C₁-C₃-alkyl, C₁-C₃-haloalkyl, C₁-C₃-alkoxy, C₁-C₄-hydroxyalkyl, C₁-C₃-haloalkoxy, C₃-C₆-cycloalkyl, and C₃-C₆-halocycloalkyl

R^a is, at each occurrence, independently selected from H, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-hydroxyalkyl, and C₃-C₆-cycloalkyl;

or two R^a, along with the nitrogen atom to which they are attached, join to form a 5 to 6 membered heterocycle containing 0-2 additional heteroatoms selected from N, O and S;

Y is 5-tetrazolyl, SO₃H, PO₂H, PO₃H₂, COOR,



R , at each occurrence, is independently selected from H, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -hydroxyalkyl, C_3 - C_7 -cycloalkyl, C_{6-10} -aryl- C_1 - C_6 -alkyl, heterocycle- C_1 - C_6 -alkyl, wherein said heterocycle is a 4-10 membered group having 1-3 heteroatoms selected from N, O, or S, said aryl and heterocycle are each substituted with 0-3 groups chosen from C_1 - C_3 -alkyl, halo, OH, or C_1 - C_3 -fluoroalkyl;

R^5 at each occurrence, is independently selected from H, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -hydroxyalkyl, C_3 - C_7 -cycloalkyl, C_3 - C_7 -cycloalkyl- C_1 - C_3 -alkyl, C_{6-10} -aryl, C_{6-10} -aryl- C_1 - C_6 -alkyl, heteroaryl, heteroaryl- C_1 - C_6 -alkyl, heterocyclyl, heterocycle- C_1 - C_6 -alkyl, wherein the heteroaryl is a 5-10 membered group and the heterocycle is a 4-10 membered each having 1-3 heteroatoms selected from N, O, or S;

Z , at each occurrence, is independently selected from a bond, O, S, $N(R^z)$, $C(R^z)_2$, $C=O$, $C(=O)N(R^z)$, $N(R^z)C(=O)$, $C(R^z)_2C(R^z)_2$, $OC(R^z)_2$, $SC(R^z)_2$, $N(R^z)C(R^z)_2$, $C(R^z)_2O$, $C(R^z)_2S$, $C(R^z)_2N(R^z)$;


R^z is at each occurrence independently selected from H, C_1 - C_4 -alkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxyalkyl, C_1 - C_4 -haloalkyl, C_3 - C_{10} -cycloalkyl, 5-10-

membered heterocycle, C₁-C₆-alkyl, 5-10 membered heterocycle, C₃-C₁₀-cycloalkyl, C₁-C₆-alkyl, 4 to 7 membered heterocycle having 1-2 heteroatoms selected from N, O, or S, or, alternatively, two R^z groups either on the same atom or on adjacent atoms can join to form a C₃-C₆-cycloalkyl or a 4 to 7 membered heterocycle containing 1-2 heteroatoms selected from N, O and S;


G is selected from a 4 to 11 membered heterocycle having 1-4 atoms selected from N, O, and S, a C₃-C₈-cycloalkyl, C₆-C₁₀-aryl or a 5 to 10 membered heteroaryl having 1-4 atoms selected from N, O, and S; wherein the heterocycle, cycloalkyl, aryl and heteroaryl are substituted with 0-3 substituents independently selected from the group consisting of -O, F, Cl, Br, I, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkyl, C₁-C₆-hydroxyalkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkenyl, CH₂-phenyl, OH, OR^{*}, SR^{*}, N(R^{*})₂, CO(R^{*}), CON(R^{*})₂, CO₂R^{*}, N(R^{*})CO₂(R^{*}), N(R^{*})CO(R^{*}), N(R^{*})CON(R^{*})₂, S(O)₂(R^{*}), S(O)₂N(R^{*})₂, or N(R^{*})S(O)₂(R^{*});

R^{*} is H, C₁₋₆-alkyl, C₁₋₄-haloalkyl, C₁₋₄-hydroxyalkyl, phenyl, CH₂-phenyl;


ring B is



Group C is



R³ is C₁₋₄-hydroxyalkyl, C₁₋₄-haloalkyl, C₁₋₆-hydroxycycloalkyl, C₁₋₆-halocycloalkyl,



COOR, CON(R^z)₂, 5-6 membered heteroaryl or


R^4 is H, F, Cl, Br, CF_3 , CN, $N(R^Z)_2$, $CON(R^Z)_2$, C_{1-4} -alkyl, C_{1-4} -haloalkyl, C_{1-4} -alkoxyalkyl, C_{1-4} -hydroxyalkyl, C_{3-6} -cycloalkyl, C_{3-6} -halocycloalkyl, C_{3-6} -alkoxycycloalkyl, C_{3-6} -hydroxycycloalkyl, or C_{3-6} -hydroxycycloalkyl;


R^5 is C_{1-6} -alkyl, C_{1-6} -haloalkyl, C_{1-6} -alkoxyalkyl, C_{3-6} -cycloalkyl, C_{0-4} -alkyl which may be substituted with 1-3 halogens or a C_{1-3} -alkoxy group;

R^6 is H, F, Cl, Br, CF_3 , CN, $N(R^Z)_2$, $CON(R^Z)_2$, C_{1-4} -alkyl, C_{1-4} -haloalkyl, C_{1-4} -alkoxyalkyl, C_{1-4} -hydroxyalkyl, C_{3-6} -cycloalkyl, C_{3-6} -halocycloalkyl, C_{1-6} -alkoxy- C_{3-6} -cycloalkyl, or C_{3-6} -hydroxycycloalkyl; and




R^7 and R^8 , are independently selected from H, C_1 - C_4 -alkyl, C_1 - C_4 -hydroxyalkyl, C_1 - C_4 -haloalkyl, C_3 - C_6 -cycloalkyl or, alternatively, R^7 and R^8 , along with the atom to which they are attached, can join to form a C_3 - C_9 -cycloalkyl, a C_3 - C_9 -halocycloalkyl, a C_3 - C_9 -hydroxycycloalkyl or a 4 to 7 membered heterocycle having 1-2 heteroatoms selected from N, O, or S each of said cycloalkyl and heterocycle being optionally substituted with 1-4 F, OH, C_{1-4} -alkyl, C_{1-4} -haloalkyl, C_{1-4} -alkoxyalkyl, or C_{1-4} -hydroxyalkyl, and may be fused with a 6 membered aryl or 5-6 membered heteroaryl ring,




provided the compounds of Formula (X) are not














11. A compound, or salt thereof, selected from:






























































12. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 11, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 10, or a pharmaceutically acceptable salt thereof.